Positive data from Phase 1 trial of RBI-4000 vaccine achieve WHO-established surrogate of protection across all dose cohorts Vector improvements demonstrate broad potential of Replicate’s srRNA for expanded indications in complex infectious disease and in situ expression of therapeutic…